Release date: 2017-06-28

Kaipu Medical Laboratory, located in Shanghai International Medical Park

Two months ago, Guangdong Kaipu Biotechnology Co., Ltd. (hereinafter referred to as Kaipu Bio) was listed on the GEM of the Shenzhen Stock Exchange. Landing in the capital market will inject more resources into scientific research.

"Cervical cancer may become the world's first cancer to be eliminated." Guan Yusheng, deputy general manager of Capt Bio, said with confidence. His self-confidence stems from the self-developed molecular diagnostic technology that can be successfully predicted 8 years before the onset of cervical cancer, which is significantly more efficient than traditional cytology screening, providing patients with adequate prevention and treatment time.

As a leading company in the national in vitro testing industry, Kaipu Bio has been effective in promoting the popularization of new technologies for cervical cancer screening. At present, the screening service population has accumulated about 16 million. At the end of last year, in the 18th China Patent Award, which was hailed as “China Intellectual Property Oscar”, the Kaipu invention patent “Human Papilloma Virus Genotyping Detection Kit and Its Gene Chip Preparation Method” won the Chinese patent. The Gold Award has become the only gold award for patent innovation in the field of in vitro diagnostics.

Study cervical cancer "culprits"

“Guangzhou Creation” won the China Invention Patent Gold Award

In the field of HPV (Human Papilloma Virus) detection nucleic acid molecule diagnosis, Capum Bio represents the current global leading level of independent innovation in China.

Guan Yusheng said that unlike other cancers, scientific research has shown that 99% of the main factors causing cervical cancer lesions are due to persistent infection of HPV virus. "It can be said that controlling HPV virus is to control cervical cancer." In order to prevent cervical cancer, Cape Bio began with its "culprit" and carried out more than ten years of special research. “It can be said that no biopharmaceutical company knows more about HPV than we do.”

The breakthrough in cervical cancer detection is from "finding the lesion" to "finding the source." According to Xie Longxu, chief scientist of Kaipu Biotechnology, the population-based screening, HPV virus detection is more suitable for first-line screening in China, which can greatly reduce the rate of missed diagnosis and improve the specificity and accuracy of screening. At the same time, they also carried out HPV typing tests, which can accurately determine whether they are persistent infections or continuous infections, classify high-risk groups and low-risk groups, and predict the risk trends of disease development. “The earliest can even be cancerous. It was detected 8 years ago and it has given patients sufficient treatment time."

At the end of last year, in the 18th China Patent Awards, which was hailed as “China Intellectual Property Oscar”, Captain’s invention of invention for HPV won the patent gold award and received a high recognition. This new technology is the first low-density gene chip technology platform. It solves the technical problems of traditional hybridization and long-term pollution, and breaks through the original US market-leading technology. Hybrid capture method can not be classified into technical obstacles, and solves HPV detection and identification of virus type. Other problems and key issues in the clinical tracking and treatment of early detection of cervical cancer, the industrialization of HPV detection at the nucleic acid level.

“The new technology we developed can shorten the hybridization time in molecular detection from the traditional 4 hours to 10 minutes, and the operation cost and application cost are greatly reduced. The inspection results are simple and easy to understand, no need for professionals to judge, and easy to popularize. "Xie Longxu analyzed.

Up to now, nearly 1,000 medical institutions across the country have used HPV testing methods to screen for cervical cancer. The number of screening services has reached about 16 million, and this year is expected to exceed 20 million. It is gradually replacing traditional cytology. For hundreds of thousands of people, the early risk of cervical cancer is indicated.

"Hand in hand" independent innovation of colleges and universities

R&D and technology into the market "tools"

With the attention to health and the development of individualized drugs, the in vitro diagnostic market has also ushered in unprecedented development. It is predicted that by 2021, the global in vitro diagnostic market will reach $7.231 billion, and the compound annual growth rate will remain at around 4%. In China, the market will reach 72.3 billion yuan in 2019, with an average compound annual growth rate of 18.7%.

In many segments of the in vitro diagnostic industry, molecular diagnostics can be widely used in infectious diseases, blood screening, hereditary diseases, molecular diagnosis of tumors, etc., and can replace other in vitro diagnostic techniques in some applications to become in vitro diagnostics. Important research and development directions in technology.

In the face of huge market space, research and development and technological advantages are becoming two of the "big tools" of Cap. As early as 2003, it established the "Hong Kong Gene Technology Co., Ltd." in cooperation with the University of Hong Kong, injecting two US patents, which became the basic framework for the early development platform.

The long-term cooperation with universities has enabled Kaipu Bio's R&D capability to rapidly increase. In the centennial celebration of the University of Hong Kong, the “hands-on” of Cap and Hong Kong University became one of the most successful technology transfer projects in the school in the past 100 years. Guan Yusheng told reporters that in addition to cooperation with Yale University and the University of Hong Kong, Captain will also develop new technologies with universities such as the Hong Kong Institute of Nanotechnology, Cambridge University and Hong Kong University of Science and Technology. At present, there are more than 200 large R&D teams in Cap Bio, including more than 30 core R&D personnel, 10 PhDs, and 100 Masters. Many academicians of the two academies serve as consultants. The team led by the chief scientist was introduced from Zhongshan University.

With the strength of independent innovation, Captain Bio has tasted the “head soup” in the molecular diagnostics market. “The market share of many products ranks among the top three in its class.” Guan Yusheng said that HPV series testing products have been popularized. Pre-pregnancy eugenics series, prenatal diagnosis and newborn screening series, Mediterranean Products such as the anemia gene detection series have achieved good response in the market.

After fully entering the field of domestic clinical testing and eugenics management, Capt Bio began to look at the international – its fist cancer products in the cervical cancer test stationed in Malaysia and Ecuador.

dialogue

Guan Yusheng, deputy general manager of Captain Bio:

Guangzhou will become a global

Biomedical industry development demonstration

Nanfang Daily: The 10th China Bio-Industry Conference is about to be held. What are the expectations of Kaipu Bio, and what projects will it bring?

Guan Yusheng: Kaipu Biotechnology, as the leader of the national HPV testing industry, is also the organizer of the “Genetic Testing Technology Progress and Development Trend Summit Forum”, and hopes to take this opportunity to bring a unique style to the participants. The feast of "gene detection helps the industrialization of precision medicine" also contributes to the development of the whole society to pay attention to the development of China's maternal and child health industry.

To this end, we invited He Lin, an academician of the Chinese Academy of Sciences, Lin Haifan, a professor at the Yale University Stem Cell Research Center, and Wang Peichang, a professor of the National Health Industry Association, to share internationally leading genetic testing techniques and explore genetic testing. The development trend and direction of precision medical industrialization.

Nanfang Daily: How do you view the biomedical development environment in Guangzhou? What development plan does Kaipu Bio settled in Guangzhou?

Guan Yusheng: The overall atmosphere in Guangzhou is very pragmatic, and there are many advantages in the biomedical industry. For example, in 2006, the Guangzhou Development Zone was recognized as the “National Bio-industry Base” by the National Development and Reform Commission. At present, Guangzhou has initially formed an industrial cluster led by health food, medical equipment and modern Chinese medicine, supplemented by advantageous industries such as precision medicine and regenerative medicine. It has a group of high-level medical institutions, research institutes and well-known enterprises. The batch of leading projects has gathered in Guangzhou, and Guangzhou has an important sample of the development of the biomedical industry in the country and the world.

In September 2015, Guangdong Kaipu Biochip R&D Industrial Base was successfully completed. The base covers an area of ​​20,000 square meters, with a construction area of ​​44,000 square meters and a designed production capacity of 500 million yuan. At present, the relevant functions of the base have been put into use one after another, and the production capacity is gradually climbing. It is estimated that the production capacity will reach 150 million yuan in 2017. The completion of the Kaipu Biochip Base has a milestone significance for the industrialization of biotechnology in the Kaipu Group.

At the same time as major achievements in molecular diagnostics R&D and production, Caper is focusing on achieving greater results in the field of clinical testing. Currently, Cape has built 20 medical testing centers, 14 of which have completed practice acceptance.

Source: Nanfang Daily

TYVEK Sterilized Packaging

Aseptic medical plastic blister trays. Producet in clean room. Special for medical device Packaging.

light weight, convenient transportation, good sealing performance, in line with the requirements of environmental protection and green packaging; Can pack any special-shaped products, packing without additional cushioning materials; The packaged products are transparent and visible, beautiful in appearance, easy to sell, and suitable for mechanization, automatic packaging, convenient for modern management, labor saving, improve efficiency

medical instruments blister tray, plastic tray

taicang hexiang packaging material co.,ltd , https://www.medpackhexiang.com